Stock listing

NASDAQ:ELDN Eledon Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Eledon Pharmaceuticals, Inc.

Follow Eledon Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ELDN

$2.27 USD +0.02 (+0.9%)

Close on Oct 15, 2026

Eledon Pharmaceuticals, Inc. logo
Ticker
NASDAQ:ELDN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2024 Earnings Call

    Thu, May 09, 2024 · 4:30 PM ET

    Watch Transcript

  • Eledon Pharmaceuticals (NASDAQ:ELDN) Q1 2023 Earnings Call

    Thu, May 11, 2023 · 4:30 PM ET

    Watch Transcript

  • Eledon Pharmaceuticals (NASDAQ:ELDN) Q4 2022 Earnings Call

    Thu, Mar 30, 2023 · 4:30 PM ET

    Watch Transcript

Latest news

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

Oct 5, 2026

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Sep 22, 2026

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Sep 9, 2026

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

Sep 3, 2026

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 13, 2026

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Jun 22, 2026

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Jun 8, 2026

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

Jun 4, 2026

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

May 20, 2026

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026

All Eledon Pharmaceuticals, Inc. news

Decks

Eledon Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 95 in all · newest Oct 5, 2026 · oldest 2021
Calls
10 calls with a replay · 10 with a transcript · latest May 9, 2024
Decks
6 decks · latest September 2026

Where Eledon Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ELDN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ELDNBOATSUnited StatesUSD
Lang & Schwarz:A2QL00Lang & SchwarzGermanyEUR
LS Exchange:A2QL00LS ExchangeGermanyEUR
Tradegate:2TKTradegateGermanyEUR
Dusseldorf:2TKDusseldorfGermanyEUR
Frankfurt:2TKFrankfurtGermanyEUR
Munich:2TKMunichGermanyEUR
Stuttgart:2TKStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Eledon Pharmaceuticals, Inc.